ABBV vs ELV: How AbbVie and Elevance Health Compare (2026)
Last updated July 2026
Short answer
ABBV is the larger of the two ($471.23B market cap): the incumbent the market prices for continued execution (16.37x forward earnings, beta 0.28). ELV is the smaller challenger ($82.72B), cheaper on forward earnings (12.87x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
ABBV vs ELV: the tie-breaker metrics
Same yardstick, side by side (as of July 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | ABBV | ELV | What it tells you |
|---|---|---|---|
| Market cap | $471.23B | $82.72B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | 16.37 | 12.87 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Trailing P/E | 130.10 | 16.88 | Valuation on the last 12 months. A big drop from trailing to forward means the market expects earnings to jump, so more growth is already in the price. |
| Beta | 0.28 | 0.68 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 100% of range | 66% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
Reading it: ELV is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.
Before you buy: how ABBV and ELV affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. ABBV and ELV share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined ABBV and ELV exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does AbbVie (ABBV) do?
AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. It focuses on discovering and commercializing medicines for immunology, oncology, neuroscience, and aesthetics. Its immunology franchise anchors the business: historically through Humira (adalimumab), and increasingly through Skyrizi (risankizumab) and Rinvoq (upadacitinib), which treat conditions such as plaque psoriasis, Crohn's disease, rheumatoid arthritis, and ulcerative colitis. Oncology contributes through Imbruvica (developed in collaboration with Johnson and Johnson) and Venclexta (in collaboration with Roche), while the 2020 acquisition of Allergan added Botox Therapeutic, Vraylar, and the aesthetics portfolio including Botox Cosmetic and Juvederm. Revenue is generated by selling branded pharmaceuticals at negotiated prices to wholesale distributors, specialty pharmacies, and health systems across more than 175 countries.
What does Elevance Health (ELV) do?
Elevance Health (formerly Anthem) is a diversified health insurer and healthcare services company that covers roughly 45.6 million medical members as of mid 2025. Its Health Benefits segment sells commercial, Medicare Advantage, Medicaid, and ACA marketplace plans, operating Blue Cross Blue Shield plans across 14 states, while its fast-growing Carelon segment houses pharmacy benefits (CarelonRx) and risk-based care services. Operating revenue reached roughly $197.6 billion in 2025, with Carelon revenue climbing about 33 percent on CarelonRx growth and the CareBridge acquisition.
ABBV vs ELV: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- ABBV drivers: Skyrizi and Rinvoq replacing Humira faster than expected; Neuroscience becoming a meaningful second growth engine.
- ELV drivers: Carelon services and pharmacy expansion; Government programs repricing.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. For ELV, the dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice.
ABBV or ELV: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick ABBV if you believe its drivers more; ELV if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the ABBV and ELV guides.
ABBV vs ELV: the full fundamentals
ABBV. The large gap between the trailing GAAP P/E (elevated, reflecting non-cash acquired IPR and D charges on recent deals) and the forward P/E of roughly 15.7x illustrates why analysts and management prefer adjusted metrics: large upfront licensing and milestone payments depress reported earnings without reducing cash generation. On a free cash flow basis, AbbVie trades at a more modest multiple, and the PEG ratio near 0.91 suggests the consensus earnings growth rate is tracking faster than the headline valuation implies. The 2026 revenue guidance of roughly $67 billion and adjusted EPS of $14.37 to $14.57 would, if achieved, represent meaningful upward re-rating from 2025 reported figures.
ELV. Elevance trades at a low double-digit earnings multiple, reflecting investor caution on medical cost trend rather than doubt about scale. Q1 2026 operating revenue was roughly $49.5 billion with adjusted EPS of about $12.58, and management raised full-year guidance while reaffirming its benefit expense ratio target near 90.2 percent. These figures are approximate and as of April 2026; verify current numbers before acting.
Headline figures (approximate, 2026-06-27): ABBV shows revenue (fy 2025, reported) ~$61.2 billion, adjusted diluted eps (fy 2025) $10.00, gaap diluted eps (fy 2025) $2.36, forward p/e (consensus fy 2026 estimate) ~15.7x; ELV shows revenue (ttm) ~$200 billion, fy2025 operating revenue ~$197.6 billion, fy2025 net income ~$5.7 billion, fy2026 adjusted eps guidance at least ~$26.75.
The bottom line: ABBV vs ELV
ABBV and ELV are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined ABBV and ELV exposure against your real portfolio. It is not an investment adviser.
Investing in AbbVie with AI
Connect the broker you already use and ask Walnut's AI how ABBV fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
What is the difference between ABBV and ELV?
+
AbbVie is a North Chicago-based research-driven biopharmaceutical company spun off from Abbott Laboratories in 2013. Elevance Health (formerly Anthem) is a diversified health insurer and healthcare services company that covers roughly 45.6 million medical members as of mid 2025. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is ABBV or ELV the better stock?
+
Neither is universally better. ABBV is the larger incumbent; ELV is the smaller challenger and looks cheaper on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, ABBV or ELV?
+
On forward P/E (as of July 2026), ABBV trades at 16.37x and ELV at 12.87x, so ELV is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both ABBV and ELV?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of ABBV vs ELV?
+
ABBV: The single largest structural risk is portfolio concentration: Skyrizi and Rinvoq together account for a rapidly growing share of total revenue, meaning any clinical setback, competitive entry in atopic dermatitis (where Regeneron's Dupixent holds a strong position), or government-mandated price cut under the Inflation Reduction Act could materially impair the growth outlook. AbbVie also carries a heavy debt load, reported at roughly $72.9 billion as of the most recent period, a legacy of the Allergan acquisition, constraining financial flexibility if credit markets tighten or a major pipeline bet fails. Ongoing integration of large acquisitions such as the pending Apogee Therapeutics deal introduces execution risk, and the aesthetics segment (Botox Cosmetic, Juvederm) has shown sensitivity to consumer spending cycles and competition from emerging aesthetic treatments. ELV: The dominant risk is medical cost trend: the benefit expense ratio (medical loss ratio) ran near 86.8 percent in Q1 2026 and rising Medicaid and Medicare utilization can compress margins faster than premiums reprice. Elevance is heavily exposed to government programs, so Medicaid rate adequacy, Medicare Advantage rate notices, and ACA subsidy policy are all regulatory swing factors outside its control. Integration risk from acquisitions like CareBridge, litigation and audit exposure common to large payers, and the political sensitivity of health insurer profits add further uncertainty. Because insurance margins are thin, a few points of adverse medical loss ratio can move earnings sharply, which is a key reason the stock carries a low multiple.
Related comparisons
Browse all stock comparisons.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell ABBV or ELV; figures are approximate and dated (as of July 2026). Verify current data before investing.